Just found this. journals.plos.org/plosmedici… It is now the 5th replication of no relationship between pre-tx expectancy and response to psychedelic therapy. Please be aware of the expectancy-myth re the action of psychedelic therapy. It has no direct evidence base.

Why Trump reversed course to fast-track psychedelic drugs for mental healthcare cnbc.com/2026/05/31/why-trum…

CAN WE CELEBRATE NOW????❤️❤️❤️❤️❤️❤️❤️❤️❤️❤️❤️

Well heck. The Arsenal. What an amazing achievement. BPM 150, dropping slowly.

The Arsenal. Your Premier League champions.

Arsenal celebrating like they’ve won the league

This is the the quote I've been citing a lot recently.

every single trade i made for years i was trying to retire on. i'd enter a position with 30-40% of my account and a number in my head: "if this hits $4m i'm out." anything less wasn't worth it. so i'd ride a 3x up. then watch it round trip. because a 3x didn't get me to my number, and selling early "wasn't worth it." did this an embarrassing number of times before it clicked. a 3x banked is rocket fuel for the next one.

Following President Trump’s directive to accelerate medical treatments for serious mental illnesses, FDA announced major steps to support the development of serotonin-2A agonists & related products—a class of medications historically referred to as "psychedelic" drugs. ✅ National priority vouchers for psilocybin (for treatment-resistant depression and major depressive disorder) ✅ National priority voucher for methylone (for post-traumatic stress disorder) ✅ First-ever noribogaine study authorized for alcohol use disorder ✅ Advancing guidance for sponsors developing these products Learn more: fda.gov/news-events/press-an…

For five years biotech startups have been betting that psychedelic substances could be turned into real medicines. One of them may have hit the jackpot econ.st/4rqmv1w Photo: Getty Images

Same point here. I think this is the main takeaway. To say it simply: on face value, Compass are still on track for approval, having played the game well.

New data from @COMPASSPathway is out. Here are my key take aways: · COMP006 met its primary endpoint – obviously 😉 · Clinically meaningful response rate jumped from 25% to 39% with two doses. This is the strongest signal that retreatment adds value. As I’ve mentioned in previous interviews and blog posts, particularly with psilocybin, I believe that some patients can, to a certain extent, “resist” the experience during their first session. Those same patients often feel safer and more familiar in subsequent sessions, which allows them to let go more fully and engage more deeply with the process. · Retreatment can push partial responders into remission. In COMP005's 26-week data, >40% of participants who had a clinically meaningful reduction but weren't in remission at week 6 achieved remission after a second dose in Part B. · Durability looks promising. Remitters showed remarkably stable remissions out to 26 weeks, and partial responders also maintained sustained partial response. This is the best commercial argument vs. Spravato's chronic dosing model. · Safety profile is clean and consistent · The "minimal support" design may have capped efficacy: Compass deliberately stripped back psychological support to isolate the drug effect for FDA. Management is now openly acknowledging that real-world clinicians adding evidence-based psychotherapy back in should yield even better outcomes. · Regulatory timeline: Q4 2026 NDA submission, early 2027 launch In short: an excellent drug that brings long-needed new treatment options to patients in real need. That said, with each new dataset it becomes clearer that while Psilocybin / COMP360 is likely to be the pioneering molecule in this space, as the field matures, next-generation treatments with shorter duration and potentially much higher efficacy - such as @ataibeckley's BPL-003 - may become the preferred standard. Also, AtaiBeckley's BPL-003 (5-MeO-DMT) and VLS-01 (DMT) fit much better into the "2 hour Spravato window", as they have the same or even shorter duration. $ATAI $CMPS ir.compasspathways.com/News-…

How was the show Silicon Valley so ahead of its time?

"AI will generate all the code, and senior programmers will review it" is basically a mantra at this point. I'm fortunate enough to know a number of top tier programmers personally, and precisely 0% of them want to spend their time reviewing AI generated code (myself included)

Be kind to each other in your neighborhood. Unite don't divide. Listen to those who hold opposing views to you and don't be part of a tribe. Have your own personal moral and ethical grounding. Work on yourself and make every effort to unite people. Those who wish to divide us wish to control us.

Almost exactly one year ago, Bessent told Kudlow that tariffs could not be inflationary “unless you give people more money” to offset the cost increase x.com/danprimack/status/1861…

Introducing Gemini 3 ✨ It’s the best model in the world for multimodal understanding, and our most powerful agentic vibe coding model yet. Gemini 3 can bring any idea to life, quickly grasping context and intent so you can get what you need with less prompting.  Find Gemini 3 Pro rolling out today in the @Geminiapp and AI Mode in Search. For developers, build with it now in @GoogleAIStudio and Vertex AI.  Excited for you to try it!

Marc Andreessen has become the avatar of societal decay, the representation of what technology looks like with no vision of the good behind it.

Sam Altman and crypto billionaire Brian Armstrong are backing a startup that wants to create genetically engineered human embryos, which is banned in the U.S. Armstrong reportedly wants to make a genetically engineered baby in secret to avoid preemptive backlash.

Please bro just subsidize our losses and then we’re good, please we’re a national strategic asset